The Global Hernia Mesh Devices Market was valued at US$ 4.5 Bn in 2021 and is expected to reach US$ 6.5 Bn by 2032, finds Future Market Insights (FMI) in a recent market survey. As per the findings of the report, Inguinal Hernia will continue to constitute 80% of all hernias. They are the most common type of hernia and it is 10X more common in men than in women. This illustrates high hernia mesh devices revenue growth through them.
Synthetic Hernia Mesh will be the Most used Mesh for Surgery throughout the Analysis Period
According to FDA, 90% of Hernia surgeries are using synthetic mesh devices. The robust supply chain, availability of raw materials, and relatively less cost are the key reasons behind the dominance of synthetic mesh in the market. The number of hernia operations in China reached 1 Mn in 2015 and is increasing by 20-30 % each following year. Hernia mesh device revenue in China is expected to reach US$ 431.1 Mn valuations by 2032.
North America will see continued revenue growth in Hernia Mesh Market throughout the Analysis Period
North America is expected to grow at 3.4% CAGR in the next decade. Reimbursement for hernia mesh is favourable in North America, which encourages patients to choose laparoscopic surgery. Patients can easily obtain comprehensive payment codes and ratios made public by governments and industry stakeholders. Furthermore, technological advancements and the development and adoption of new goods, such as TELA Bio, are propelling the entire market forward in terms of revenue.
“Despite the 90% dominance of synthetic mesh in the Hernia Mesh device market, the biological mesh-based hernia devices can reap significant market revenue in the forthcoming years” comments an analyst at Future Market Insights.
Hernia Mesh Devices Market: Competition Insights
Most of the key players in hernia mesh devices market have been focusing on obtaining approvals from regulatory authorities. The key companies operating in the Hernia Mesh Devices market include Medtronic plc, Ethicon, and W. L. Gore and Associates, Inc., Atrium Medical Technologies, B. Braun Melsungen AG, PRIMEQUAL SA, Becton, Dickinson, and Company, Deep Blue Medical Inc., Dipromed Srl, BioCer Entwicklungs-GmbH, Betatech Medical, Sinolinks Medical Innovation, Inc, Aspide Medical S.A.S., Meril Life Sciences Pvt. Ltd., Herniamesh Srl., Changzhou Medical Equipment General Factory Co., Ltd, Gem Srl, SAMYANG HOLDING CORPORATION, Katsan Katgut Sanayi Ve Ticaret Anonim Sirketi, Novus Scientific AB.
The key recent developments of Hernia Mesh Devices manufacturers are as follows:
- In Mar 2020, Novus Scientific AB received FDA approval for TIGR Matrix Surgical Mesh indicated for use in procedures involving soft tissue repairs, such as for the repair of hernias or other soft tissue-related defects.
- In Jul 2020, Becton, Dickinson, and Company received FDA clearance for 3DMax MID Anatomical Mesh indicated for use in the reinforcement of soft tissue, and repair of inguinal hernias.
- In Aug 2020, Deep Blue Medical Inc., secured the clearance of the U.S. FDA for commencing the sale of its new hernia mesh product. The promising sales opportunities of the product have led the company to recently announce its equity of US$ 3.4 Mn in the company by investors.
